Member Info for Stateside

Thanks Paul. Much appreciated.

RightOn. You're probably correct.
Would be good to know exactly what they're doing I suppose. Happy to leave them to it.

RightOn. You say that no more drilling at Empire is needed? Have you seen the Tweet today?
htTps://twitter.com/Phoenix_Copper/status/1543898678313848832

Nice report aandi.
I see that Longspur also cover PHE and VLS.
I wouldn't be surprised if they recommended them as well.
You pays your money etc. etc.

I sent an email to Investor relations asking just that for todays presentation - we'll see.
They're probably just going to ignore him.

C909: Tom Winnifrith didn't mention the loan at all. Maybe he didn't read about that??
Just a quick and cheap shot at Eqt from my pov.

Ooh! You're right ! Whoops !!

Thanks to Skinny on the other site.
https://www.prnewswire.com/news-releases/covanta-and-eqt-infrastructure-to-create-a-standalone-waste-to-energy-platform-in-europe-301530712.html

Really appreciate your time that you spend here and giving us (lesser knowledged peeps ) confidence in our Eqt shares.
The detail on these projects can be daunting to me but well explained.
Brilliant job mate. Please keep it up.

... mean't 0.6p.
Wouldn't 6p be great ??
:-))

...... but acceptable in these times don'tcha think?
Better than a rights issue at what? 6p maybe.

I was delighted to be introduced at the AGM today as the new head of IR for the UK.

Thanks to Jeff/PantsonFire for introducing me to the board and suggesting I fulfil this role, and also to the board for seeing the opportunity it could offer.

I think one of the drivers behind my appointment is that the board recognise that the investment landscape has changed and the AIM market is increasingly dominated by retail investors. They want to use a range of platforms to keep that sector informed about the company, and I can help achieve that. One aspect of AIM is that companies become "stale" quite quickly, as investors often think they understand the story and then move onto the next big thing.
So my goal will be to make sure that people understand the PXC strategy, and that when PXC has news to report, it is released in a way that reaches the maximum number of people and is expressed in a way that is easily understood. It's not about ramping or artificially creating news, just making sure that headlines aren't buried in small print and that presentations cover the right topics at the right time. The board have always been keen on giving retail investors as much information as possible, and I regard my role as simply to continue that good work and let them focus their time on bringing the fantastic project to fruition.

It goes without saying that its not a role I would have taken on had I not felt so positive about the company.

sajy. Yes. You're most probably mad :-)
It was my second largest investment. I'm 65% down at the moment but forever hopeful. When the s..t hit the fan I was unable to sell so I'm here for the long run (the story of my investment life)
Looking good at the moment - 13% up as I type.
GLA

https://www.calvinepartners.com/diurnal-group-smc-decision

You may have to register.

Decent RNS this morning. 14 countries to be added to Alkindi distribution list.
Keep chipping away guys.

Did he have to mention the phrase "fund raise" twice ??
Lordy, lordy Duncan !!

FPTP:
We will be losing out in sales in the UK as a whole (as I understood it) because lots of medical centres and authorities, use SMC's analysis and rulings to determine what drugs are ok to use.
I wonder if the directors are being ultra cautious. After all we were granted marketing authority in July 2021 :

Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has granted a Marketing Authorisation for Efmody® (hydrocortisone modified-release hard capsules – development name Chronocort®) as treatment of adult and adolescent patients (12 years and older) with the rare condition congenital adrenal hyperplasia (CAH). The Marketing Authorisation for Efmody® from the MHRA applies in Great Britain (England, Wales and Scotland) and follows the recent approval of the product in the European Economic Area (including Northern Ireland)(EEA) by the European Commission as announced on 28 May 2021.

Correction from Timbo - "It was not a missed milestone in 2018, it was a missed primary endpoint in a clinical trial in 2018"

In response to questions in the "Investor Meets Company" at lunchtime, Martin or Richard - not sure which - said that SMC's decision was based around the company missing a trial date in 2018 !!
The fact that Efmodi has been passed by UK & EU didn't seem to matter and Efmodi is still being prescribed in Scotland.
Seems VERY harsh.

I would like to know what exactly went wrong with the SMC/Efmody approval?
Simply a paperwork ****-up by Dnl or test results weren't as good as SMC requires???